CVS Health (CVS) Q3 2026 Earnings Call Transcript

CVS Health reported third-quarter revenue of $108.4 billion, up 5.4%, and adjusted EPS of $2.09, up more than 30% year over year; it raised 2026 adjusted EPS guidance to at least $8.20 and operating cash flow guidance to at least $15.5 billion. The company plans to separate into two publicly traded businesses by the first half of 2028, subject to board approval and customary conditions. Management set a 2027 adjusted EPS floor of $8.65 and expects Health Services earnings to be at least $7 billion, which it described as the segment’s trough; share repurchases are expected to resume in Q4 2026.

Analysis

The separation is a potential valuation catalyst, but it also turns today’s internal transfer pricing into two companies’ external bargaining problem. Caremark’s economics depend partly on pharmacy access and service models; commercial agreements may preserve products, but renewal terms could shift value between CVS Health and CVS Pharmacy or encourage clients to use competing networks. That risk is more consequential than the stated goal of simpler capital allocation, and it may benefit competing PBMs such as Express Scripts and Optum if negotiations create friction.

Near term, the earnings recovery is more tangible than the 2028 transaction: Medicare pricing and utilization execution support the outlook, while elevated medical-cost trends remain a reversal risk. Health Services has a visible 2027 trough, but 340B stabilization and renewed Caremark growth are management expectations, not yet demonstrated outcomes. Retail prescription growth and AI-supported workflow may improve capacity, but neither establishes durable margin expansion on its own. Health 100 is also an execution dependency: splitting ownership while promising interoperability creates governance and incentive questions, not just an upside option.

The contrarian risk is treating the split as automatic sum-of-the-parts value creation. Standalone public-company costs, debt allocation, and weaker operating coordination could offset focus benefits. Buybacks are not a clear incremental EPS catalyst in the 2027 floor: management described them as offsetting dilution. Over the next 1–3 months, watch formal 2027 guidance and Aetna enrollment/pricing outcomes; over 6–18 months, watch Caremark client retention, 340B contribution, and separation costs. No valuation or market-price data are supplied, so the breakup premium is not yet actionable as a standalone trade.

Key Decisions for Investors

• For existing CVS holders, retain a core position rather than buying solely on breakup optionality. Reassess after formal 2027 guidance and the next update on Medicare Advantage enrollment and margins.
• Stage any additions only after checking valuation and the February outlook; the operating recovery supports the case, but the 2027 EPS floor does not appear to rely on material buyback accretion.
• Treat the separation as a watch item, not a near-term catalyst trade. Seek disclosure on debt allocation, stranded costs, tax conditions, and binding commercial agreements between the two companies before assigning a sum-of-the-parts premium.
• Falsify the recovery thesis if medical-cost trends push Aetna results below guidance, Caremark client attrition or 340B declines exceed the stated plan, or management reduces the Health Services earnings floor or delays separation milestones.